Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
33 studies found for:    " September 22, 2010":" October 22, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" September 22, 2010":" October 22, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
Condition: HIV Infections
Interventions: Biological: Ad35-ENV vaccine;   Biological: Ad26.ENVA.01 vaccine;   Biological: Placebo Control
2 Completed
Has Results
Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients
Condition: HIV Infection
Intervention: Drug: Azithromycin
3 Completed Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants
Condition: HIV Infections
Intervention:
4 Completed
Has Results
Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
Conditions: HIV Infections;   Heart Disease
Interventions: Drug: Rosuvastatin 10 mg. daily for 96 weeks;   Drug: Placebo
5 Completed HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Conditions: Chronic HIV Infection;   HCV Coinfection
Intervention: Drug: Fosamprenavir
6 Active, not recruiting Prevalence of Liver Fibrosis and Progression of Liver Fibrosis
Condition: HIV Infection and Chronic Alanine Aminotransferase Elevation
Intervention: Other: Fibroscan
7 Completed
Has Results
A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
Condition: HIV-1 Infection
Intervention: Drug: Raltegravir
8 Completed
Has Results
Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
Condition: HIV
Interventions: Drug: Truvada;   Drug: Raltegravir
9 Unknown  Measurement of Plasma and Intracellular Concentrations of Raltegravir
Condition: HIV
Intervention: Drug: Raltegravir
10 Active, not recruiting Study to Improve Survival Among HIV-Exposed Infants in Botswana
Conditions: HIV Infections;   Neutropenia;   Anemia
Interventions: Drug: cotrimoxazole prophylaxis;   Drug: cotrimoxazole placebo;   Behavioral: exclusive breastfeeding until 6 months of age;   Behavioral: breastfeeding for 12 months
11 Terminated Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections
Condition: HIV
Intervention:
12 Unknown 
Has Results
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572 (dolutegravir);   Drug: raltegravir;   Other: GSK1349572 Placebo;   Other: ABC/3TC;   Other: TDF/FTC;   Other: raltegravir Placebo
13 Completed Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.
Conditions: 1- Women;   2- HIV Infection;   3- Followed in West Indies and French Guiana for His Infection;   4- Acceptance of the Use of Nadis® Medical Files
Intervention: Other: Biological Sample collection
14 Completed Multi-vitamins, HAART and HIV/AIDS in Uganda
Condition: HIV/AIDS
Intervention: Dietary Supplement: Multivitamin supplements B,C and E
15 Unknown  Chinese Network of Pediatric Antiretroviral Therapy
Condition: Acquired Immunodeficiency Syndrome
Intervention:
16 Unknown  Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients
Conditions: Human Immunodeficiency Virus;   Disorder of Immune Reconstitution
Interventions: Drug: high dose of MSC;   Drug: low dose of MSC treatment
17 Completed Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
Conditions: Drug Interactions;   Human Immunodeficiency Virus
Intervention: Drug: Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)
18 Unknown 
Has Results
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1349572;   Drug: Raltegravir;   Drug: GSK1349572 Placebo;   Drug: Raltegravir Placebo
19 Terminated Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 100 mg once daily;   Drug: GSK2248761 200 mg once daily;   Drug: Efavirenz 600 mg once daily
20 Active, not recruiting Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
Condition: Reduction in Heavy Drinking in Patients With HIV
Interventions: Drug: Naltrexone;   Other: Placebo + Medication Management/Medication Coaching

   Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.